Selank

A synthetic heptapeptide analog of tuftsin examined in preclinical neuropharmacology, gene-expression, and neuroimmune signaling research models.

View Selank in the store

Molecular Profile

Type
Synthetic heptapeptide (tuftsin analog)
Molecular formula
C33H57N11O9
Molecular weight
751.88 g/mol
CAS number
129954-34-3
Amino acids
7
Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
Modification
Free termini; tuftsin (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro motif to confer protease resistance. N-Acetyl Selank adds N-terminal acetylation as a further stability modification.

Mechanism & Target Class

A linear heptapeptide analogue of the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended at the C-terminus with a Pro-Gly-Pro motif reported to confer resistance to peptidase cleavage. Research on the parent compound describes several studied mechanisms: concentration-dependent inhibition of enkephalin-degrading enzymes in human serum, examined in relation to endogenous enkephalin hydrolysis; modulation of GABAergic-system gene expression studied at the transcriptional level; effects on monoamine systems (serotonin, dopamine, norepinephrine) measured by HPLC in brain structures; and regulation of BDNF expression and cytokine/chemokine gene expression. N-Acetyl Selank is the N-terminally acetylated variant; its pharmacological properties are inferred from parent-compound studies, as no dedicated peer-reviewed literature exists for the acetylated form.

Storage & Handling

Lyophilized
-20°C, protected from light and moisture; stable long term.
Handling
Hydrophilic and water-soluble; aliquot to avoid repeated freeze-thaw cycles; protect from light.

Primary Database

PubChem CID 11765600 ↗

References (27)

  1. Reviews

    1

    Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM. (2022). Pharmaceutics

    DOI: 10.3390/pharmaceutics14040716PubMed 35456550

  2. 2

    Kolomin T, et al. (2018). Protein Pept Lett

    DOI: 10.2174/0929866525666180925144642PubMed 30255741

  3. 3

    Kolomin TA, et al. (2019). Biology Bulletin

    DOI: 10.1134/S1062359019040071

  4. Clinical

    4

    Panikratova YaR, et al. (2020). Doklady Biological Sciences

    DOI: 10.1134/S001249662001007XPubMed 32342318

  5. 5

    Medvedev VE, Tereshchenko ON, Israelyan AYu, Chobanu IK, Kost NV, Sokolov OYu, Myasoedov NF. (2014). Zh Nevrol Psikhiatr Im S S Korsakova

    PubMed 25176261

  6. 6

    Zozulia AA, et al. (2008). Zh Nevrol Psikhiatr

    PubMed 18454096

  7. 7

    Uchakina ON, et al. (2008). Zh Nevrol Psikhiatr

    PubMed 18577961

  8. Primary research

    8

    Filippenkov IB, Glazova NYu, Sebentsova EA, et al. (2024). Nanobiotechnology Reports

    DOI: 10.1134/S2635167624601335

  9. 9

    Konstantinopolsky MA, Chernyakova IV, Kolik LG. (2022). Bull Exp Biol Med

    DOI: 10.1007/s10517-022-05624-xPubMed 36322304

  10. 10

    Kolik LG, Nadorova AV, et al. (2019). Bull Exp Biol Med

    DOI: 10.1007/s10517-019-04588-9PubMed 31625062

  11. 11

    Povarov IS, Kondratenko RV, Derevyagin VI, Myasoedov NF, Skrebitsky VG. (2017). Bull Exp Biol Med

    DOI: 10.1007/s10517-017-3676-3PubMed 28361410

  12. 12

    Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, et al. (2017). Front Pharmacol

    DOI: 10.3389/fphar.2017.00089PubMed 28293190

  13. 13

    Volkova A, et al. (2016). Front Pharmacol

    DOI: 10.3389/fphar.2016.00031PubMed 26924987

  14. 14

    Kolomin T, et al. (2014). Molecular Immunology

    DOI: 10.1016/j.molimm.2013.11.002

  15. 15

    Kolomin TA, et al. (2014). Neuroscience and Behavioral Physiology

    DOI: 10.1007/s11055-014-9992-4PubMed 24450168

  16. 16

    Solov'ev VB, Gengin MT, et al. (2012). J Evol Biochem Physiol

    DOI: 10.1134/S0022093012030073PubMed 22827026

  17. 17

    Kolomin TA, Shadrina MI, Agniullin YaV, et al. (2010). Doklady Biochemistry and Biophysics

    DOI: 10.1134/S1607672910010023

  18. 18

    Andreeva LA, Ershov FI, et al. (2009). Vopr Virusol

    PubMed 19882898

  19. 19

    Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. (2009). Eksp Klin Farmakol

    PubMed 19803361

  20. 20

    Narkevich VB, et al. (2008). Eksp Klin Farmakol

    PubMed 19093364

  21. 21

    Inozemtseva LS, Karpenko EA, Dolotov OV, et al. (2008). Doklady Biological Sciences

    DOI: 10.1134/S0012496608040066

  22. 22

    Semenova TP, Kozlovskaya MM, Zuikov AV, et al. (2008). Neuroscience and Behavioral Physiology

    DOI: 10.1007/s11055-008-0030-2PubMed 18197389

  23. 23

    Zolotarev YuA, Sokolov OYu, Kost NV, et al. (2004). Russian Journal of Bioorganic Chemistry

    DOI: 10.1023/B:RUBI.0000030126.09208.c3PubMed 15344652

  24. 24

    Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. (2003). Neuroscience and Behavioral Physiology

    DOI: 10.1023/A:1025988519919PubMed 14969422

  25. 25

    Sokolov OYu, Meshavkin VK, Kost NV, Zozulya AA. (2002). Bull Exp Biol Med

    DOI: 10.1023/A:1015582302311PubMed 12432865

  26. 26

    Kost NV, Sokolov OYu, Gabaeva MV, et al. (2001). Russian Journal of Bioorganic Chemistry

    DOI: 10.1023/A:1011373002885

  27. 27

    Kost NV, et al. (2001). Bull Exp Biol Med

    DOI: 10.1023/a:1017915302484PubMed 11550013